Dr. Jonah Sacha

Dr. Jonah Sacha

Dr. Sacha graduated cum laude from the University of Missouri-Columbia in 2003 with a B.A. in German and B.S. in Biology.  After receiving his Ph.D. in Medical Microbiology & Immunology from the University of Wisconsin-Madison in 2007, he joined the faculty at UW-Madison, where he researched the characteristics of effective retrovirus-specific CD8+ and CD4+ T cells.  In 2011, he joined the Oregon Health & Science University and has appointments in both the Vaccine & Gene Therapy Institute and Oregon National Primate Research Center.

Dr. Sacha will lead CytoDyn’s team efforts in HIV PreP and HIV cure.

Dr. Hope Rugo

Dr. Hope Rugo

Dr. Hope Rugo is the Director of the Breast Oncology Clinical Trials Program at UCSF.  She is the principal investigator for multiple clinical trials studying novel targeted therapeutics combined with standard treatments to improve clinical results in early and late-stage breast cancer.  She is also researching cognitive function in patients receiving chemotherapy for breast cancer as well as ways to reduce toxicity from therapy.

Dr. Rugo has established collaborations with several large academic medical centers to expand the novel therapies that are available to patients. She is an active member of the national cooperative group, CALGB, a founding member of the Breast Cancer Research Consortium, and an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer).

Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally, and internationally. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families, and friends from throughout the Bay Area.  She is widely published and highly regarded in the field of oncology.

Dr. Otto Yang

Dr. Otto Yang

Dr. Otto Yang is a Professor of Medicine, Infectious Diseases, Microbiology, Immunology & Molecular Genetics at UCLA and has a background in clinical infectious diseases. His laboratory specializes in T cell immunology in HIV infection, relevant to developing immune therapies and vaccines for HIV and potentially other diseases including cancer and other viral infections. He received his MD degree from Brown University, with subsequent residency training at NYU-Bellevue Hospital and subspecialty/postdoctoral training at Harvard-Massachusetts General Hospital. He then pursued fellowship at Massachusetts General Hospital, where he developed a research program studying the role of CD8+ T lymphocytes (CTL, which are killer T cells that can destroy cells infected with viruses or which are malignant) in HIV-1 pathogenesis. A more recent research interest has been the role of CTL in the development of rejection in organ transplant patients. Dr. Yang has begun working with the new composite tissue transplantation program at UCLA, which will perform hand and face transplants, studying the role of this arm of immunity in causing tissue rejection. Dr. Yang is a frequent lecturer, received numerous research grants and funding for his work, published over 180 peer-reviewed articles, and holds numerous patents in HIV and Immunology.

Dr. Paul Edison

Dr. Paul Edison

Dr. Paul Edison is a Clinical Senior Lecturer in Neuroscience in the Department of Brain Sciences at Imperial College London and an honorary Professor at Cardiff University. He is also the Editor-in-Chief of the journal Brain Connectivity. After his clinical training (MD), Dr. Edison received his MPhil and PhD from Imperial College London, and then completed his higher training in London Deanery and obtained his CCT from the Postgraduate Medical Education and Training Board. He then became a Fellow of Royal College of Physicians, Ireland and Fellow of Royal College of Physicians, UK. He has published in high impact journals such as Brain, Annals of Neurology, and Neurology, and has received grants from the Medical Research Council, NIHR/HEFCE, Alzheimer’s Society, Alzheimer’s Research UK, Alzheimer’s Drug Discovery Foundation US, and other funders. He collaborates closely with Novo Nordisk, GE Healthcare, Novartis, Piramal Life Sciences, and Astra Zeneca. He has also received several best paper awards internationally and published in leading scientific journals. His work now focuses on neuroinflammation, and the interplay between inflammation and immunity in neurodegenerative and neuroinflammatory disease and relating these with genetic information. He is also evaluating the methods of modulating inflammation and amyloid in Alzheimer’s disease, and the influence of cardiometabolic factors on the development of neurodegenerative diseases by means of clinical and pre-clinical studies. 

Dr. Mazen Noureddin

Dr. Mazen Noureddin

Dr. Mazen Noureddin is a hepatologist at Cedars Sinai in Los Angeles. He completed his residency at the University of Southern California and completed a hepatology fellowship at the NIH and gastroenterology fellowship at University of California San Diego.  

Dr. Noureddin has led efforts in several breakthrough clinical trials targeting new therapies in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those with advanced fibrosis and cirrhosis.  He also focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver transplant, liver cancer, new imaging modalities, and exploring new treatments.

His work has been featured in Gastroenterology, Hepatology, and The American Journal of Gastroenterology, among many others.

Dr. Kabir Mody

Dr. Kabir Mody

Dr. Kabir Mody is the Medical Director at IMV, Inc. and a board-certified medical oncologist. He brings a wealth of experience and knowledge in oncology and immuno-oncology accumulated while working at Mayo Clinic as an academic oncologist focused on GI oncology, in particular cancers of the liver and the pancreas. Dr. Mody received his MD from St. George's University School of Medicine, completed his residency at St. Luke’s-Roosevelt Hospital in New York City and fellowship at Dartmouth Hitchcock Medical Center in New Hampshire. He has co-authored numerous papers and book chapters, including many on the biology and novel treatment strategies of liver and pancreas malignancies, and has been actively involved in leading both clinical and lab-based research on cancers of the liver and pancreas. 

Dr. Norman Gaylis

Dr. Norman Gaylis

Dr. Norman Gaylis is recognized as one of the country’s leaders in the field of arthritis and rheumatic diseases. He is board-certified in Internal Medicine and Rheumatology and has been a practicing Rheumatologist in the greater Miami area for more than 35 years. Dr. Gaylis completed his training as a rheumatologist at the University of Miami, where he served on the clinical faculty for many years. 

Dr. Gaylis is the owner and chief operating officer of AARDS Research, Inc., a clinical research organization specializing in clinical research trials for autoimmune diseases and the Medical Director of Infusion and Immunotherapy Center of South Florida (IIC.) He has been a Principal Investigator in over 200 clinical trials for new pharmaceutical products for the treatment of Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus, Lupus Nephritis, Gout, and Sjogren’s syndrome.

Dr. Gaylis has presented numerous scientific papers and has conducted medical meetings around the United States and internationally.  He is the author of multiple peer-reviewed articles, focused in particular on the subjects of rheumatoid arthritis, magnetic resonance imaging in rheumatology, and other rheumatic disorders.  He is the past medical director for the Rheumatology division at Cardinal Health, a speaker and consultant for numerous pharmaceutical companies and the recipient of many awards and honors, as well as an active member of the American College of Rheumatology and the Rheumatology Research Foundation.

Dr. Eric Mininberg

Dr. Eric Mininberg

Dr. Eric Mininberg is a board-certified medical oncologist at Piedmont Cancer Institute and a Diplomat of the American Board of Internal Medicine.  He graduated from Dartmouth College in 1993 with a degree in government and obtained a medical degree from the University of Virginia School of Medicine. He completed his residency at the University of Virginia Medical Center. He was a Hematology fellow at Baylor University and a Medical Oncology fellow at the University of Texas MD Anderson Cancer Center.

Dr. Mininberg is the recipient of numerous honors and awards. He was inducted in 1989 as a member of Cum Laude Society with St. Albans School in Washington, DC. While at The University of Texas MD Anderson Cancer Center, he was honored with the Elsa U. Pardee Foundation Grant for Community Oncology. As a fellow in 2003 he was awarded the American Society of Clinical Oncology Merit Award. He holds memberships with the Dartmouth and University of Virginia Alumni Associations, as well as the American and Georgia Societies of Clinical Oncology.

He has numerous publications and abstracts in Hematology and Oncology. 

Dr. Mininberg will specifically support CytoDyn’s clinical trial enrollment in the southeast region and further exploration of leronlimab PRO 140’s indications in oncology.

Dr. Gero Hütter

Dr. Gero Hütter

Gero Hütter is a German hematologist who developed and performed the first allogeneic transplantation with natural CCR5 depleted stem cells in a leukemia patient with HIV-infection in 2004, during his residency in hematology, oncology and transfusion medicine at Charité Hospital in Berlin, Germany.  Since then, the patient who is now known as “the Berlin patient,” has not resumed antiretroviral therapy, nor has he had a relapse of HIV disease.

In 2009, Dr Hütter became the head of the stem cell unit of the Institute of Transfusion Medicine and Immunology Mannheim of the Heidelberg University. There, he directs the research group of personalized stem therapy, which is supported by a grant from the Bill & Melinda Gates foundation.

Dr. Jacob (Jay) Lalezari

Dr. Jacob (Jay) Lalezari

Dr. Lalezari has agreed to serve as an outside Scientific Advisor to CytoDyn without compensation. Dr. Lalezari has been the CEO and Medical Director of Quest Clinical Research since 1997. He received his MD degree from the University of Pennsylvania and his MA from the University of Virginia. He also received a BA from the University of Rochester. He received his board certification from the American Board of Internal Medicine. He briefly served as interim Chief Medical Officer of CytoDyn during 2020, as well as Chief Medical Officer of Virion Therapeutics. Dr. Lalezari has served as Principal Investigator for Phase I, II, and III clinical studies of new therapies for such viral diseases as HIV/AIDS, CMV, HPV, HSV, Hepatitis B and C, Influenza, RSV, and COVID-19, including clinical trials conducted by the Company. He has published extensively and is a well-regarded international speaker and patient advocate.